Sherie L. Morrison

Sherie L. Morrison's AcademicInfluence.com Rankings

Sherie L. Morrison

Biology

#8884

World Rank

#12022

Historical Rank

Immunology

#520

World Rank

#537

Historical Rank

Molecular Biology

#1159

World Rank

#1185

Historical Rank

biology Degrees

Download Badge

Biology

Sherie L. Morrison's Degrees

PhD Molecular Biology Stanford University
Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Sherie L. Morrison Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sherie L. Morrison's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene (1983) (1035)
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. (1984) (982)
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. (1989) (514)
Effect of glycosylation on antibody function: implications for genetic engineering. (1997) (321)
Immunoglobulin gene expression in transformed lymphoid cells. (1983) (318)
Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. (1995) (300)
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. (1988) (277)
The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region (1991) (275)
Structural features of human immunoglobulin G that determine isotype- specific differences in complement activation (1993) (257)
Production of human monoclonal antibody in eggs of chimeric chickens (2005) (205)
Design and production of novel tetravalent bispecific antibodies (1997) (204)
Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. (1992) (199)
Transfectomas provide novel chimeric antibodies. (1985) (198)
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1 (1994) (192)
Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor (2000) (168)
Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. (1998) (147)
The N-Glycans Determine the Differential Blood Clearance and Hepatic Uptake of Human Immunoglobulin (Ig)a1 and Iga2 Isotypes (2000) (142)
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain (1991) (138)
Glycosylation of a VH residue of a monoclonal antibody against alpha (1- ---6) dextran increases its affinity for antigen (1988) (132)
Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. (1990) (123)
A Quantitative Difference in the Immune Response between Male and Female Mice∗ (1968) (123)
A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. (1991) (119)
Human IgG2 Can Form Covalent Dimers1 (2003) (104)
Antibody-cytokine fusion proteins for the therapy of cancer. (2001) (103)
Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. (2010) (102)
In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. (2000) (99)
Transferrin-antibody fusion proteins are effective in brain targeting. (1995) (94)
Sequences in antibody molecules important for receptor-mediated transport into the chicken egg yolk. (2002) (93)
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. (2006) (93)
Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression. (2004) (90)
In vitro antibodies: strategies for production and application. (1992) (88)
Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. (1999) (87)
Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans. (1987) (86)
Genetically engineered antibody molecules. (1989) (85)
An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. (1999) (84)
A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. (1999) (80)
Recombinant Anti-Human HER2/neu IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity1 (2000) (80)
Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody (2007) (78)
Heavy chain-producing variants of a mouse myeloma cell line. (1975) (76)
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells (2002) (76)
Production and properties of chimeric antibody molecules. (1989) (73)
Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. (1995) (72)
Myeloma mutant with a novel 3' flanking region: loss of normal sequence and insertion of repetitive elements leads to decreased transcription but normal processing of the alpha heavy-chain gene products (1986) (71)
Detection of specific hybridoma clones by replica immunoadsorption of their secreted antibodies. (1979) (69)
Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. (2003) (68)
Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigens. (1982) (68)
Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection (2007) (65)
Structural Requirements for Polymeric Immunoglobulin Assembly and Association with J Chain* (1999) (62)
Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. (1986) (61)
Production of secretory immunoglobulin A by a single mammalian cell. (1997) (60)
IgA: an immune glycoprotein. (2005) (60)
Influence of the Isotype of the Light Chain on the Properties of IgG1 (2002) (60)
Two heads are better than one (2007) (60)
Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis-derived monoclonal rheumatoid factors. (1993) (59)
Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function. (1997) (59)
In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. (1996) (59)
Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. (2015) (59)
Genetically engineered antibodies: progress and prospects. (1992) (59)
Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. (1992) (58)
Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains. (1995) (58)
The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin g (1994) (56)
Plasma Cells Are Obligate Effectors of Enhanced Myelopoiesis in Aging Bone Marrow. (2019) (56)
Targeting of functional antibody-CD59 fusion proteins to a cell surface. (1999) (56)
Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. (1994) (55)
Myeloma expression systems. (2002) (55)
In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. (1999) (55)
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. (2006) (54)
The Role of Constant Region Carbohydrate in the Assembly and Secretion of Human IgD and IgA1* (2002) (53)
Murine heavy chain disease (1978) (52)
Cleavage of the Human Immunoglobulin A1 (IgA1) Hinge Region by IgA1 Proteases Requires Structures in the Fc region of IgA (2003) (52)
Polypeptide products of nonsense mutations. I. Termination fragments from nonsense mutations in the Z gene of the lac operon of Escherichia coli. (1970) (52)
Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. (2014) (50)
Targeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities1 (2007) (47)
Characterization of the Interaction between the Herpes Simplex Virus Type I Fc Receptor and Immunoglobulin G* (1999) (47)
Immunochemical characterization of binding sites of hybridoma antibodies specific for α(1 → 6) linked dextran☆☆☆★ (1982) (46)
Sequences of variable regions of hybridoma antibodies to alpha (1----6) dextran in BALB/c and C57BL/6 mice. (1985) (46)
A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. (1998) (46)
Regulation of immunoglobulin expression in mouse myeloma cells. (1977) (45)
Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin (1994) (45)
Expression of a VHCκ chimaeric protein in mouse myeloma cells (1984) (44)
Characterization of the J chain from polymeric immunoglobulins (IgA-IgM-immunological specificity-primary structure). (1972) (44)
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein (2005) (42)
A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. (2001) (42)
Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. (1998) (41)
V Region Carbohydrate and Antibody Expression1 (2004) (41)
Antibody-cytokine fusion proteins: innovative weapons in the war against cancer (2004) (40)
Structure and Function of Several Anti-Dansyl Chimeric Antibodies Formed by Domain Interchanges between Human IgM and Mouse IgG2b (*) (1995) (40)
Studies on mouse hybridomas secreting IgM or IgA antibodies to α(1→6)-linked dextran☆ (1981) (39)
Functional and pharmacokinetic properties of antibody-avidin fusion proteins. (1997) (39)
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. (1993) (39)
Sequences near the 3' secretion-specific polyadenylation site influence levels of secretion-specific and membrane-specific IgG2b mRNA in myeloma cells (1986) (39)
Association constants of hybridoma antibodies specific for α(1 → 6) linked dextran determined by affinity electrophoresis☆☆☆ (1982) (39)
Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. (1994) (38)
Production and characterization of genetically engineered antibody molecules. (1988) (38)
Recombinant Polymeric IgG: An Approach to Engineering More Potent Antibodies (1994) (37)
Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting. (1990) (37)
Residues critical for H-L disulfide bond formation in human IgA1 and IgA2. (1996) (36)
Mutational events in mouse myeloma cells. (1981) (35)
Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. (1993) (35)
Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. (2008) (34)
Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface* (2001) (34)
Genetically Engineered Antibody Molecules and Their Application (1987) (33)
A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-α Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia (2005) (33)
Mapping IgG epitopes bound by rheumatoid factors from immunized controls identifies disease-specific rheumatoid factors produced by patients with rheumatoid arthritis. (1998) (33)
A common sequence motif near nonhomologous recombination breakpoints involving Ig sequences. (1993) (33)
Transfer and expression of immunoglobulin genes. (1984) (32)
Formation of hybridoma clones in soft agarose: Effect of pH and of medium (1980) (32)
Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. (2002) (32)
Production and characterization of recombinant IgA. (1999) (32)
Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer (2009) (31)
Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines (2010) (30)
Antibody variable region glycosylation: biochemical and clinical effects (2004) (30)
Development of new models for the analysis of Fc-FcRn interactions. (2006) (30)
Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. II. Effect of varying the antigen-antibody ratio and the amount of immune complex injected. (1966) (29)
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors (2013) (29)
A RANTES-antibody fusion protein retains antigen specificity and chemokine function. (1998) (28)
An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma. (2019) (28)
Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). (2001) (28)
Expression of Novel Secreted Isoforms of Human Immunoglobulin E Proteins (*) (1996) (28)
Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins. (1979) (28)
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. (2001) (28)
A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. (2005) (27)
Role of Complement in Protection against Cryptococcus gattii Infection (2008) (27)
Two alpha heavy chain disease proteins with different genomic deletions demonstrate that nonexpressed alpha heavy chain genes contain methylated bases. (1981) (27)
The hinge as a spacer contributes to covalent assembly and is required for function of IgG. (1997) (26)
Anti-CD20-Interferon-&bgr; Fusion Protein Therapy of Murine B-Cell Lymphomas (2013) (26)
Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity (2009) (26)
Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. 3. The role of antigen in controlling the immune response elicited with immune complexes. (1967) (26)
Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. (2006) (26)
Bifunctional fusion between nerve growth factor and a transferrin receptor antibody (1997) (26)
Loss of a consensus splice signal in a mutant immunoglobulin gene eliminates the CH1 domain exon from the mRNA (1984) (25)
The IgD CH1 region contains the binding site for the human respiratory pathogen Moraxella catarrhalis IgD‐binding protein MID (2006) (25)
An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. (1995) (24)
Molecular analysis of IgM rheumatoid factor binding to chimeric IgG. (1991) (24)
Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. (1972) (24)
An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. (1998) (24)
Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. (2005) (22)
The role of carbohydrate in the assembly and function of polymeric IgG. (2000) (22)
Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement. (1997) (21)
Production and characterization of a murine/human chimeric anti-idiotype antibody that mimics ganglioside. (1992) (21)
Transformation of E. coli by electroporation. (2001) (21)
Cloning, Expression, and Modification of Antibody V Regions (2002) (20)
Functional properties of antibody insulin-like growth factor fusion proteins. (1994) (19)
Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma. (2015) (19)
Cysteine Residues Required for the Attachment of the Light Chain in Human IgA21 (2002) (19)
14 – Chimeric Immunoglobulin Genes (1989) (19)
Somatically generated mouse myeloma variants synthesizing IgA half- molecules (1981) (18)
Design and engineering human forms of monoclonal antibodies (2004) (18)
Biochemical characterization of a differentiation antigen shared by human epidermal langerhans cells and cortical thymocytes. (1982) (18)
Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein (2005) (18)
Recombinant chimeric monoclonal antibodies. (1990) (18)
Production and characterization of monoclonal antibodies to the subunits of human phosphofructokinase: new tools for the immunochemical and genetic analyses of isozymes. (1981) (18)
Characterization of IgA and IgM binding and internalization by surface-expressed human Fcα/μ receptor. (2011) (17)
A colorimetric-enzymatic microassay for the quantitation of antibody-dependent complement activation. (1999) (17)
Amino acid substitutions in VH CDR2 change the idiotype but not the antigen-binding of monoclonal antibodies to alpha(1----6)dextrans. (1989) (17)
A mouse myeloma variant with a defect in light chain synthesis (1979) (17)
Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization. (1998) (16)
Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma (2016) (16)
Structural and functional properties of mouse-human chimeric IgD. (1992) (15)
Sequences 3’of Immunoglobulin Heavy Chain Genes Influence their Expression (1986) (15)
Variable region domain exchange influences the functional properties of IgG. (1998) (14)
Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. (2006) (14)
Antibody-IL-2 fusion proteins: a novel strategy for immune protection. (1997) (13)
Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer (2017) (13)
A variant of the dextran-binding mouse plasmacytoma J558 with altered glycosylation of its heavy chain and decreased reactivity with polymeric dextran. (1981) (13)
The SRC Family Tyrosine Kinase HCK and the ETS Family Transcription Factors SPIB and EHF Regulate Transcytosis across a Human Follicle-associated Epithelium Model* (2013) (13)
Genetically engineered antibodies and their application to brain delivery. (1995) (12)
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy (2015) (12)
Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions. (2004) (12)
Incomplete assembly of IgA2m(2) in Chinese hamster ovary cells. (2007) (12)
In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways. (2011) (12)
Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2‐fluoro‐2′‐deoxyadenosine and the cytotoxic drug, 2‐fluoroadenine (2009) (11)
An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding. (1996) (11)
A Rapid and Economic In-House DNA Purification Method Using Glass Syringe Filters (2009) (11)
Mapping rheumatoid factor binding sites using genetically engineered, chimeric IgG antibodies. (1992) (11)
Structure-function studies of anti-3-fucosyllactosamine (Le(x)) and galactosylgloboside antibodies. (1994) (11)
Genetically engineered antibody molecules: new tools for cancer therapy. (1988) (11)
The novel human IgE epsilon heavy chain, epsilon tailpiece, is present in plasma as part of a covalent complex. (2000) (10)
ICR-191 and ethyl methanesulfonate induced mutagenesis at the immunoglobulin locus in the Y5606 cultured myeloma cell line. (1981) (10)
THE USE OF MUTANT MYELOMA CELLS TO EXPLORE THE PRODUCTION OF IMMUNOGLOBULINS (1975) (10)
Genetically‐Engineered Antibodies: Tools for the Study of Diverse Properties of the Antibody Molecule (1992) (10)
Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT (2009) (10)
A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells. (1985) (10)
Transposon-directed base-exchange mutagenesis (TDEM): a novel method for multiple-nucleotide substitutions within a target gene. (2009) (9)
An analysis of heavy chain glycopeptides of hybridoma antibodies: correlation between antibody specificity and sialic acid content. (1981) (9)
Heavy-chain mutants derived from gamma 2b mouse myeloma: characterization of heavy-chain messenger ribonucleic acid, proteins, and secretion in delection mutants and messenger ribonucleic acid in gamma2a mutant progeny. (1981) (9)
The effect of isotype and the J kappa region on antigen binding and idiotype expression by antibodies binding alpha (1----6) dextran. (1989) (9)
New differentiation antigens associated with the growth and maturation of B lymphocytes. (1988) (9)
A cross-reactive idiotype, QUPC52 IdX, present on most but not all anti-alpha (1 replaced by 6) dextran-specific IgM and IgA hybridoma antibodies with combining sites of different sizes. (1982) (9)
Regulation of the production of secretory and membrane immunoglobulin during lymphocyte development. (1989) (9)
N-Terminal Domain-Deleted Mu Transposase Exhibits Increased Transposition Activity with Low Target Site Preference in Modified Buffers (2008) (9)
Developmental regulation of membrane and secretory Ig gamma 2b mRNA. (1989) (9)
Estimation of antibodies specific for dextran. (1978) (8)
Expression of a VHC kappa chimaeric protein in mouse myeloma cells. (1984) (8)
An insertion-deletion event in murine immunoglobulin kappa gene resembles mutations at heavy-chain disease loci (1993) (8)
Polypeptide products of nonsense mutations. II. Minor fragments produced by nonsense mutations in the z gene of the lactose operon of Escherichia coli. (1971) (8)
An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery. (2005) (8)
Genetically engineered (chimeric) antibodies. (1989) (7)
Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents. (2009) (7)
Isolation and characterization of a variant of mouse plasmacytoma J558 synthesizing a 110,000-dalton immunoglobulin heavy chain and of secondary variants synthesizing either a 55,000-dalton or an 80,000-dalton immunoglobulin heavy chain: possible implications (1982) (7)
Inhibitors of MyD88-Dependent Proinflammatory Cytokine Production Identified Utilizing a Novel RNA Interference Screening Approach (2009) (6)
Recombinant IgA Antibodies (2007) (6)
The pllaswoacfloma J558b lacks constitutivdy active NF-×B and is deficient in early response gene activation (1991) (6)
Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha. (2018) (6)
Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran. (1982) (6)
Engineering novel antibody molecules. (1996) (6)
Specificity and variable region cDNA sequence of an isogeneic monoclonal antiidiotype to an anti-alpha(1----6)dextran. (1991) (6)
Alternative splicing patterns in an aberrantly rearranged immunoglobulin kappa-light-chain gene. (1985) (6)
The identification of mouse myeloma cells which have undergone mutations in immunoglobulin production. (1974) (6)
A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity (2001) (6)
Engineering Novel Antibody Molecules (Part 1 of 2) (1996) (5)
Biological Activity of a Mouse-Human Chimeric Immunoglobulin G2 Antibody to Cryptococcus neoformans Polysaccharide (2002) (4)
An immunoglobulin heavy chain gene deletion at direct repeats: nucleotide sequence and effect on mRNA accumulation. (1988) (4)
Studies on mouse hybridomas secreting IgM or IgA antibodies to alpha(1 to 6)-linked dextran. (1981) (4)
Two Ig framework I epitopic specificities recognized by a rabbit antiserum and a monoclonal antibody to mouse VH chains. (1990) (4)
The plasmacytoma J558L lacks constitutively active NF-kappa B and is deficient in early response gene activation. (1991) (4)
Genetic Engineering of Antibody Molecules (2015) (4)
Intron sequences determine the expression of kappa light chain genes. (1994) (4)
Antibody structure and antibody engineering (1988) (3)
Spontaneous deletions in Ig heavy chain genes: flanking sequences influence splice site selection. (1991) (3)
Antibody‐Complement Interaction (2009) (3)
Association constants of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran determined by affinity electrophoresis. (1982) (3)
Preparing frozen bacterial stocks. (2001) (3)
The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications. (1992) (3)
Hybrid antibodies. (1993) (3)
Chimeric Antibodies: Production and Applications (1995) (3)
C57BL/6 x BALB/c hybridomas produce IgA which assembles into molecules with covalent bonds between heavy chains (H) and light chains (L), and into molecules lacking covalent bonds between H and L. (1985) (2)
Complement Activation and Fc Receptor Binding by IgG (1993) (2)
Sequence of the γ2b membrane 3' untranslated region: Polya site determination and comparison to the γ2a membrane 3' untranslated region (1992) (2)
Production of novel immunoglobulin molecules by gene transfection. (1986) (2)
IMMUNE DEGRADATION IN PASSIVELY SENSITIZED MICE. II. DEGRADATION OF HUMAN AND BOVINE SERUM ALBUMIN IN MICE CONCOMITANTLY INJECTED WITH VARIOUS HETEROLOGOUS ANTISERA. (1965) (2)
Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas (2015) (2)
New approaches to the production of monoclonal antibodies. (1988) (2)
Constant Region Mutants of Mouse Immunoglobulins (1979) (2)
Antibody-fused interferons as an effective approach to enhance target specificity and antiviral efficacy of type I interferons (2008) (1)
Anti-CD138-IFNα Fusion Proteins Are Effective in Treating Multiple Myeloma (2012) (1)
Efficient Identification of Human Immunodeficiency Virus Type 1 Mutants Resistant to a Protease Inhibitor by Using a Random Mutant Library (2011) (1)
Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo (2011) (1)
Mutants of Chinese Hamster Ovary Cells Mouse-Human IgG1 Antibodies in Glycosylation on Ig Effector Function: Studies with Chimeric Effect of C2-Associated Carbohydrate Structure (1998) (1)
Title A CD 19 / Fc fusion protein for detection of anti-CD 19 chimeric antigen receptors (2013) (1)
Antisense Oligonucleotide Induces Synthetic Lethality in HK 1-HK 2 + Multiple Myeloma (2019) (1)
Cytotoxic Activity of Anti-CD20-hIFN-α on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy, (2011) (1)
The IgA myeloma W3129 contains a deletion in CH3 which prevents the formation of the membrane form of heavy chain mRNA. (1988) (1)
Antibody Fusion Proteins: Applications in Brain Targeting (2002) (1)
20 The Role of Glycosylation in Engineered Antibodies (2005) (1)
Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro (2013) (1)
Rabbit antisera to the variable region domains of an anti-alpha(1----6) dextran using E. coli-produced VL and VH fusion proteins as immunogens. (1990) (1)
Human:Mouse Antibody-Producing Transfectoma Cell Lines (1985) (0)
Characterization of two bi-functional anti-HER2/neu IgG3-cytokine fusion proteins with potential use as cancer therapeutics (2004) (0)
Antisense Drug Delivery to the Brain Targeting : Initial Applications in Anti-HIV Delivery Vehicle for Effective Brain for the Transferrin Receptor Serves as a An Antibody-Avidin Fusion Protein Specific Pardridge (1999) (0)
Antigen on Human CancersM 3 to Ganglioside G Molecular Cloning of a Human Monoclonal Antibody Reactive Updated (2006) (0)
598 The monoclonal IgM rheumatoid factor (mIgM RF) binding site: Essential amino acids in CH2 and CH3 domains of genetically engineered chimeric IgG (cIgG) (1991) (0)
Antibody Molecules, Genetic Engineering of (2006) (0)
In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells (2019) (0)
Conjugues anticorps monofonctionnels ou bifonctionnels en tant qu'adjuvants efficaces de vaccination proteique (2006) (0)
Demonstrates Antitumor Activity Antigen Specificity and Cytokine Function IgG 3-( GM-CSF ) Fusion Protein Retains neu Recombinant Anti-Human HER 2 / (2000) (0)
Engineering Novel Antibody Molecules (Part 2 of 2) (1996) (0)
Immunoglobulin synthesis and secretion (2003) (0)
(cloning in agarose/nitrocellulose filters/monoclonal antibodies/erythrocyte adherence assay/autoradiography) (2016) (0)
A new design for bispecific antibodies enables efficient production of stable molecules with good pharmacodynamic properties. (2007) (0)
Abstract 1726: Preclinical evaluation of a novel tumor selectively targeted and activated immunocytokine platform (2021) (0)
89Zr-ImmunoPET shows therapeutic efficacy of anti-CD20 interferon-α fusion protein in a murine B-cell lymphoma model. (2022) (0)
Identification and functional characterization of a highly conserved sequence in the intron of the kappa light chain gene. (1996) (0)
Modification du domain de la region constant des anticorps (1989) (0)
Transfection of Lymphoid Cells (1994) (0)
Control Elements Located within the Major Intervening Sequences of Murine Kappa Light Chain Genes (1984) (0)
Antibody having modified carbohydrate content, its production and use (1989) (0)
Alternative splicing patterns inanaberrantly rearranged immunoglobulin C-light-chain gene (1985) (0)
the Properties of IgG Influence of the Isotype of the Light Chain on (2001) (0)
Mechanism of apoptosis induced by an IgG3-avidin fusion protein specific for the human transferrin receptor (2005) (0)
V-region glycosylation and antigen binding in monoclonal anti-α(I→6)dextrans : Structure and function of glycosylation in cell regulation and differentiation (1992) (0)
Activity of anti-CD20-interferon-α fusion protein against human B-cell lymphomas. (2011) (0)
Antitumor Activity IL-12 Bioactivity and Demonstrates Protein Retains Antibody Specificity and A Single-Chain IL-12 IgG3 Antibody Fusion (1999) (0)
CHARACTERIZATION OF A RANTES-ANTIBODY FUSION PROTEIN FOR CANCER IMMUNOTHERAPY (1997) (0)
Antibody with modified carbohydrate content and methods of making and using (1989) (0)
Chimean antibodies with receptor-binding ligands rather than your constant region (1991) (0)
This information is current as Functional Properties of IgG Variable Region Domain Exchange Influences the (1998) (0)
519 Recombinant antigen-specific IgG and IgA, but not IgE, induces degranulation and superoxide production by human eosinophils (2000) (0)
OR5 Igg subclass and concentration are determinants of HLA class I antibody capacity to fix complement in in vitro clinical and functional assays (2015) (0)
Production and Characterization of a Murine / Human Chimeric Anti-Idiotype Antibody That Mimics Ganglioside 1 (2006) (0)
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors (2013) (0)
Production and Characterization of a Murine/Human Chimeric Anti-Idiotype Antibody That Mimics Ganglioside1 (2006) (0)
A Note on HUMAN:MOUSE ANTIBODY-PRODUCING TRANSFECTOMA CELL LINES (1985) (0)
Antigen Specificity and Chemokine Function A RANTES-Antibody Fusion Protein (1998) (0)
Both the lectin and alternative pathways of complement activation play roles in Cryptococcus gattii infection (2008) (0)
TRANSFECTOMAS PROVIDE ANTIBODIES WITH NOVEL STRUCTURES AND FUNCTIONS (1987) (0)
Efﬁcient Identiﬁcation of Human Immunodeﬁciency Virus Type 1 Mutants Resistant to a Protease Inhibitor by Using a Random Mutant Library (cid:1) (2011) (0)
188 Targeted delivery of endostatin using an antibody-endostatin fusion protein resulted in enhanced inhibition of tumor growth (2004) (0)
Modification of the constant region domain of antibodies (1989) (0)
Nomenclature and Constructs of C Region Domains for Chimeric Abs Used in this Study (2003) (0)
Patients with Rheumatoid Arthritis Disease-Specific Rheumatoid Factors Produced Factors from Immunized Controls Identifies Mapping IgG Epitopes Bound by Rheumatoid (1998) (0)
and Demonstrates Antitumor Activity Antigen Specificity and Cytokine Function IgG3-(GM-CSF) Fusion Protein Retains neu Recombinant Anti-Human HER2/ (2000) (0)
Synergistic Inhibition of Multiple Myeloma Growth by Anti-CD138-Interferon-alpha14 Fusion Protein and Lenalidomide (2018) (0)
Genetically engineered antibodies with improved functional properties (1996) (0)
Ibrutinib plus anti-CD20-interferon alpha fusion protein for treatment of B cell lymphomas. (2016) (0)
Molecular Cloning of a Human Monoclonal Antibody Reactive to Ganglioside GM 3 Antigen on Human Cancers 1 (2006) (0)
Sequence of the gamma 2b membrane 3' untranslated region: polya site determination and comparison to the gamma 2a membrane 3' untranslated region. (1992) (0)
Characterization of the J Chain from Pol (IgA/IgM/immunological specificity/primary structure) (2016) (0)
The novel human IgE epsilon heavy chain, epsilon tailpiece, is present in plasma as part of a covalent complex: [Mol. Immunol. (2000) 37(5) 241–252] (2001) (0)
SHORT ANALYTICAL REVIEW Antibody-Cytokine Fusion Proteins: Harnessing the Combined Power of Cytokines and Antibodies for Cancer Therapy 1 (2002) (0)
A United States Patent ( 19 ) 11 Patent Number : 5 , 977 , 307 Friden (2017) (0)
Expression of genes containing the IgH enhancer in non-lymphoid cells. (1990) (0)
T Cell Costimulatory Pathway Antibody Specificity and Ability to Activate Via A B 7 . 1-Antibody Fusion Protein (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sherie L. Morrison?

Sherie L. Morrison is affiliated with the following schools:

Sherie L. Morrison's Academic­Influence.com Rankings

Sherie L. Morrison's Degrees

Similar Degrees You Can Earn

Why Is Sherie L. Morrison Influential?

Sherie L. Morrison's Published Works

Published Works

What Schools Are Affiliated With Sherie L. Morrison?

Sherie L. Morrison's AcademicInfluence.com Rankings